Search Within

Ryan Brett Sugarman

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (4)
Groups
  1. Department of Medicine (9)
  2. Department of Pathology and Laboratory Medicine (9)
  3. Gastrointestinal Oncology Service (9)
  4. Solid Tumor Oncology Division (9)
  5. Survivorship Research (8)
  6. Biostatistics Service (7)

More Groups

People
  1. Laura Tang (7)
  2. David Ilson (6)
  3. Geoffrey Ku (6)
  4. Steven Maron (6)
  5. Yelena Janjigian (6)
  6. Avni Desai (5)

More People

Years
  1. 2025 (1)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (1)
  5. 2020 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. Nature (2)
  3. Annals of Oncology (1)
  4. Annals of Surgery (1)
  5. Lancet Oncology (1)
  6. New England Journal of Medicine (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Nature Publishing Group (2)
  3. Elsevier Science, Inc. (1)
  4. Lippincott Williams & Wilkins (1)
  5. Massachusetts Medical Society (1)
  6. Oxford University Press (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
    Journal Article

    Sethna, Z.; Guasp, P.; Reiche, C.; Milighetti, M.; Ceglia, N.; Patterson, E.; Lihm, J.; Payne, G.; Lyudovyk, O.; Rojas, L. A.; more...
    Nature (2025)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab and PET-directed chemoradiation in locally advanced esophageal adenocarcinoma: A phase Ib/II study
    Journal Article

    Cowzer, D.; Wu, A. J. C.; Sihag, S.; Walch, H. S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; more...
    Annals of Surgery (2023)

    Fulltext@MSK | Save
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
    Journal Article

    Rojas, L. A.; Sethna, Z.; Soares, K. C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results
    Meeting Abstract

    Cowzer, D.; Wu, A. J. C.; Sihag, S.; Walch, H. S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer
    Journal Article

    Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Lamendola-Essel, M.; El Dika, I. H.; Segal, N.; Shcherba, M.; Sugarman, R.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
    Meeting Abstract

    Ku, G. Y.; Wu, A. J. C.; Sihag, S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma
    Meeting Abstract

    Ly, M.; Molena, D.; Sihag, S.; Wu, A. J. C.; Shah, P. M.; Gu, P.; Sugarman, R.; Maron, S. B.; Chalasani, S. B.; Shcherba, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save